16:07:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-29 Bokslutskommuniké 2023
2023-11-20 Extra Bolagsstämma 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning GEAN 0.00 NOK
2023-05-11 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-01 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-13 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning GEAN 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-09-20 Extra Bolagsstämma 2021

Beskrivning

LandNorge
Lista5542285
SektorHälsovård
IndustriBioteknik
Genetic Analysis är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling inom området för diagnostik, med störst fokus mot mänsklig mikrobiomet. Tekniken utgår ifrån bolagets forskningsplattform och IVD-produkterna används exempelvis för testtagning och analys av bakterier och virus. Störst verksamhet återfinns inom den nordiska marknaden och produkterna vidaresäljs huvudsakligen till laboratorier. Bolaget har sitt huvudkontor i Oslo, Norge.
2022-08-18 10:44:48

Correction: Correction of the previously disclosed press release since the headline stated January - March. The correct timeline for the interim report is January - June. Otherwise, there are no changes from the previously published press release.

Oslo, Norway, August 18, 2022 - Genetic Analysis AS ("GA" or "the Company") hereby publishes the interim report for the period January 1 - June 30, 2022. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Genetic Analysis CEO Ronny Hermansen comments:
"As the first six months of 2022 have passed, I am proud to say that we keep on delivering on our objectives set out in the IPO. In the past quarter, we continued our preparation to expand globally to major markets and entered a strategic collaboration agreement to further develop new microbiome diagnostic and therapeutic solutions and a distribution agreement to launch GA-map® to the United Arabic Emirates (UEA) market. Strategic collaborations and partners like these enable us to accelerate our momentum to become a leading diagnostic company within the microbiome field and they fit perfectly with our business strategy."

Q2 2022 (01.04.2022 - 30.06.2022)
  • Operating income amounted to NOK 5,5 million (2,0)
  • Sales amounted to NOK 3,0 million (1,3)
  • Net profit/loss amounted to NOK -6,1 million (-6,9)
  • Total assets amounted to NOK 70,1 million (43,9)
  • Equity ratio amounted to 83,2% (74,3)
  • Earnings per share amounted to NOK -0,24 (-0,40)
H1 2022 (01.01.2022 - 30.06.2022)
  • Operating income amounted to NOK 10,3 million (3,4)
  • Sales amounted to NOK 5,5 million (2,3)
  • Net profit/loss amounted to NOK -13,8 million (-15,1)
  • Total assets amounted to NOK 70,1 million (43,9)
  • Equity ratio amounted to 83,2% (74,3)
  • Earnings per share amounted to NOK -0,55 (-0,88)
Highlights Q2 2022
  • Total operating income of NOK 5,5 million in Q2 2022, up 177% from Q2 2021. Net loss was NOK -6,1 million compared to NOK -6,9 million in the corresponding quarter of 2021.
  • Sales revenues of NOK 3,0 million, a 123% growth compared to Q2 2021. Reagent kit sales grew by 113% from NOK 1,0 million in Q2 2021 to NOK 2,2 million in Q2 2022.
  • On June 22, GA entered a Strategic Collaboration Agreement together with Servatus Biopharmaceuticals Ltd. to develop new microbiome diagnostic and therapeutic solutions. The collaboration will bring together Servatus world class knowledge of biotherapeutics and GA's microbiome diagnostic signature analysis to develop new diagnostic markers and treatment options to ultimately improve the lives of patients worldwide.
  • On May 19, GA entered a distribution agreement with Omnigene Medical Technologies Ltd. to launch GA-map® in the United Arabic Emirates market. In the first stage of the collaboration, Omnigene will launch the GA-map® Dysbiosis Test to the market in Malta.
  • In Q2, GA received notification acceptance for two posters at the American Association for Clinical Chemistry (AACC) congress in Boston in July 2022, which underlines the strength in GA's biomarker discovery programs. The posters addressed both the GA healthy population study performed in North America, and a type 2 diabetes microbiota observational study.
  • In Q2, GA announced that both Mangold and Norne Securities initiated analyst coverage of the company. The reports can be read at GA's website www.genetic-analysis.com/analystcoverage/.
  • On April 28, GA held an Annual General Meeting. The Minutes from the AGM with summarized decisions are available on the Company's website (www.genetic-analysis.com).
Highlights after the period
  • No significant events have occurred after the period that has materially affected this report.